Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 3/2005

Open Access 01-03-2005 | Research article

Levels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis

Authors: Ola Grimsholm, Solbritt Rantapää-Dahlqvist, Sture Forsgren

Published in: Arthritis Research & Therapy | Issue 3/2005

Login to get access

Abstract

It is well known that cytokines are highly involved in the disease process of rheumatoid arthritis (RA). Recently, targeting of neuropeptides has been suggested to have potential therapeutic effects in RA. The aim of this study was to investigate possible interrelations between five neuropeptides (bombesin/gastrin-releasing peptide (BN/GRP), substance P (SP), vasoactive intestinal peptide, calcitonin-gene-related peptide, and neuropeptide Y) and the three cytokines tumour necrosis factor (TNF)-α, IL-6, and monocyte chemoattractant protein-1 in synovial fluid of patients with RA. We also investigated possible interrelations between these neuropeptides and soluble TNF receptor 1 in serum from RA patients. Synovial fluid and sera were collected and assayed with ELISA or RIA. The most interesting findings were correlations between BN/GRP and SP and the cytokines. Thus, in synovial fluid, the concentrations of BN/GRP and SP grouped together with IL-6, and SP also grouped together with TNF-α and monocyte chemoattractant protein-1. BN/GRP and SP concentrations in synovial fluid also grouped together with the erythrocyte sedimentation rate. In the sera, BN/GRP concentrations and soluble TNF receptor 1 concentrations were correlated. These results are of interest because blocking of SP effects has long been discussed in relation to RA treatment and because BN/GRP is known to have trophic and growth-promoting effects and to play a role in inflammation and wound healing. Furthermore, the observations strengthen a suggestion that combination treatment with agents interfering with neuropeptides and cytokines would be efficacious in the treatment of RA. In conclusion, BN/GRP and SP are involved together with cytokines in the neuroimmunomodulation that occurs in the arthritic joint.
Appendix
Available only for authorised users
Literature
1.
Kaltreider HB, Ichikawa S, Byrd PK, Ingram DA, Kishiyama JL, Sreedharan SP, Warnock ML, Beck JM, Goetzl EJ: Upregulation of neuropeptides and neuropeptide receptors in a murine model of immune inflammation in lung parenchyma. Am J Respir Cell Mol Biol. 1997, 16: 133-144.CrossRefPubMed
2.
Gamse R, Posch M, Saria A, Jancso G: Several mediators appear to interact in neurogenic inflammation. Acta Physiol Hung. 1987, 69: 343-354.PubMed
3.
Foreman JC: Peptides and neurogenic inflammation. Br Med Bull. 1987, 43: 386-400.PubMed
4.
Metwali A, Blum AM, Ferraris L, Klein JS, Fiocchi C, Weinstock JV: Eosinophils within the healthy or inflamed human intestine produce substance P and vasoactive intestinal peptide. J Neuroimmunol. 1994, 52: 69-78. 10.1016/0165-5728(94)90164-3.CrossRefPubMed
5.
Maggi CA: The effects of tachykinins on inflammatory and immune cells. Regul Pept. 1997, 70: 75-90. 10.1016/S0167-0115(97)00029-3.CrossRefPubMed
6.
Lotz M, Carson DA, Vaughan JH: Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science. 1987, 235: 893-895.CrossRefPubMed
7.
Cerinic MM, Konttinen Y, Generini S, Cutolo M: Neuropeptides and steroid hormones in arthritis. Curr Opin Rheumatol. 1998, 10: 220-235.CrossRefPubMed
8.
Alstergren P, Appelgren A, Appelgren B, Kopp S, Lundeberg T, Theodorsson E: Co-variation of neuropeptide Y, calcitonin gene-related peptide, substance P and neurokinin A in joint fluid from patients with temporomandibular joint arthritis. Arch Oral Biol. 1995, 40: 127-135. 10.1016/0003-9969(94)00141-W.CrossRefPubMed
9.
Appelgren A, Appelgren B, Eriksson S, Kopp S, Lundeberg T, Nylander M, Theodorsson E: Neuropeptides in temporomandibular joints with rheumatoid arthritis: a clinical study. Scand J Dent Res. 1991, 99: 519-521.PubMed
10.
Hernanz A, De Miguel E, Romera N, Perez-Ayala C, Gijon J, Arnalich F: Calcitonin gene-related peptide II, substance P and vasoactive intestinal peptide in plasma and synovial fluid from patients with inflammatory joint disease. Br J Rheumatol. 1993, 32: 31-35.CrossRefPubMed
11.
Westermark T, Rantapaa-Dahlqvist S, Wallberg-Jonsson S, Kjorell U, Forsgren S: Increased content of bombesin/GRP in human synovial fluid in early arthritis: different pattern compared with substance P. Clin Exp Rheumatol. 2001, 19: 715-720.PubMed
12.
Spindel ER, Krane IM: Molecular biology of bombesin-like peptides. Comparison of cDNAs encoding human gastrin-releasing peptide, human neuromedin B, and amphibian ranatensin. Ann N Y Acad Sci. 1988, 547: 10-20.CrossRefPubMed
13.
Anastasi A, Erspamer V, Bucci M: Isolation and structure of bombesin and alytesin, 2 analogous active peptides from the skin of the European amphibians Bombina and Alytes. Experientia. 1971, 27: 166-167.CrossRefPubMed
14.
Pert A, Moody TW, Pert CB, Dewald LA, Rivier J: Bombesin: receptor distribution in brain and effects on nociception and locomotor activity. Brain Res. 1980, 193: 209-220. 10.1016/0006-8993(80)90958-0.CrossRefPubMed
15.
Okuma Y, Yokotani K, Osumi Y: Centrally applied bombesin increases nerve activity of both sympathetic and adrenal branch of the splanchnic nerves. Jpn J Pharmacol. 1995, 68: 227-230.CrossRefPubMed
16.
Larsson J, Ekblom A, Henriksson K, Lundeberg T, Theodorsson E: Concentration of substance P, neurokinin A, calcitonin gene-related peptide, neuropeptide Y and vasoactive intestinal polypeptide in synovial fluid from knee joints in patients suffering from rheumatoid arthritis. Scand J Rheumatol. 1991, 20: 326-335.CrossRefPubMed
17.
Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP: Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med. 2001, 7: 563-568. 10.1038/87887.CrossRefPubMed
18.
Takeba Y, Suzuki N, Kaneko A, Asai T, Sakane T: Evidence for neural regulation of inflammatory synovial cell functions by secreting calcitonin gene-related peptide and vasoactive intestinal peptide in patients with rheumatoid arthritis. Arthritis Rheum. 1999, 42: 2418-2429. 10.1002/1529-0131(199911)42:11<2418::AID-ANR21>3.0.CO;2-7.CrossRefPubMed
19.
Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D: VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J Neuroimmunol. 1999, 96: 167-181. 10.1016/S0165-5728(99)00023-5.CrossRefPubMed
20.
Martinez C, Delgado M, Pozo D, Leceta J, Calvo JR, Ganea D, Gomariz RP: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J Leukoc Biol. 1998, 63: 591-601.PubMed
21.
Delgado M, Ganea D: Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. J Immunol. 2001, 167: 966-975.CrossRefPubMed
22.
Sun L, Ganea D: Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production through different molecular mechanisms in T cells activated via the T cell receptor/CD3 complex. J Neuroimmunol. 1993, 48: 59-69. 10.1016/0165-5728(93)90059-8.CrossRefPubMed
23.
Brennan FM, Maini RN, Feldmann M: TNF alpha – a pivotal role in rheumatoid arthritis?. Br J Rheumatol. 1992, 31: 293-298.CrossRefPubMed
24.
Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl G, deWoody K, et al: Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999, 163: 1521-1528.PubMed
25.
Hidaka T, Suzuki K, Kawakami M, Okada M, Kataharada K, Shinohara T, Takamizawa-Matsumoto M, Ohsuzu F: Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis. J Clin Apheresis. 2001, 16: 74-81. 10.1002/jca.1016.CrossRefPubMed
26.
Manicourt DH, Poilvache P, Van Egeren A, Devogelaer JP, Lenz ME, Thonar EJ: Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. Arthritis Rheum. 2000, 43: 281-288. 10.1002/1529-0131(200002)43:2<281::AID-ANR7>3.0.CO;2-7.CrossRefPubMed
27.
Saxne T, Palladino MA, Heinegard D, Talal N, Wollheim FA: Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum. 1988, 31: 1041-1045.CrossRefPubMed
28.
Ulfgren AK, Lindblad S, Klareskog L, Andersson J, Andersson U: Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis. 1995, 54: 654-661.PubMedCentralCrossRefPubMed
29.
Marinova-Mutafchieva L, Williams RO, Mason LJ, Mauri C, Feldmann M, Maini RN: Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clin Exp Immunol. 1997, 107: 507-512. 10.1046/j.1365-2249.1997.2901181.x.CrossRefPubMed
30.
Heilig B, Wermann M, Gallati H, Brockhaus M, Berke B, Egen O, Pezzutto A, Hunstein W: Elevated TNF receptor plasma concentrations in patients with rheumatoid arthritis. Clin Investig. 1992, 70: 22-27. 10.1007/BF00422933.CrossRefPubMed
31.
Cope AP, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones AC, Brennan FM, Maini RN, Wallach D, Feldmann M: Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum. 1992, 35: 1160-1169.CrossRefPubMed
32.
Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J, Chwiecko J: Circulating tumour necrosis factor alpha and soluble tumour necrosis factor receptors in patients with different patterns of rheumatoid synovitis. Ann Rheum Dis. 2003, 62: 472-475. 10.1136/ard.62.5.472.PubMedCentralCrossRefPubMed
33.
Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J: Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988, 31: 784-788.CrossRefPubMed
34.
Yoshimura T, Robinson EA, Tanaka S, Appella E, Leonard EJ: Purification and amino acid analysis of two human monocyte chemoattractants produced by phytohemagglutinin-stimulated human blood mononuclear leukocytes. J Immunol. 1989, 142: 1956-1962.PubMed
35.
Yoshimura T, Robinson EA, Tanaka S, Appella E, Kuratsu J, Leonard EJ: Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J Exp Med. 1989, 169: 1449-1459. 10.1084/jem.169.4.1449.CrossRefPubMed
36.
Gong JH, Ratkay LG, Waterfield JD, Clark-Lewis I: An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med. 1997, 186: 131-137. 10.1084/jem.186.1.131.PubMedCentralCrossRefPubMed
37.
Harigai M, Hara M, Yoshimura T, Leonard EJ, Inoue K, Kashiwazaki S: Monocyte chemoattractant protein-1 (MCP-1) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium. Clin Immunol Immunopathol. 1993, 69: 83-91. 10.1006/clin.1993.1153.CrossRefPubMed
38.
Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines GK, Burdick MD, Pope RM, Strieter RM: Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest. 1992, 90: 772-779.PubMedCentralCrossRefPubMed
39.
Lotz M, Vaughan JH, Carson DA: Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science. 1988, 241: 1218-1221.CrossRefPubMed
40.
Kim WK, Kan Y, Ganea D, Hart RP, Gozes I, Jonakait GM: Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway. J Neurosci. 2000, 20: 3622-3630.PubMed
41.
Cuesta MC, Quintero L, Pons H, Suarez-Roca H: Substance P and calcitonin gene-related peptide increase IL-1 beta, IL-6 and TNF alpha secretion from human peripheral blood mononuclear cells. Neurochem Int. 2002, 40: 301-306. 10.1016/S0197-0186(01)00094-8.CrossRefPubMed
42.
Kane DJ, Lockhart J, Balint PV, Mann C, Ferrell W, McInnes IB: Protective effect of sensory denervation in inflammatory arthritis evidence of regulatory neuroimmune pathways in the arthritic joint. Ann Rheum Dis. 2005, 64: 325-327. 10.1136/ard.2004.022277.PubMedCentralCrossRefPubMed
43.
Arnalich F, de Miguel E, Perez-Ayala C, Martinez M, Vazquez JJ, Gijon-Banos J, Hernanz A: Neuropeptides and interleukin-6 in human joint inflammation relationship between intraarticular substance P and interleukin-6 concentrations. Neurosci Lett. 1994, 170: 251-254. 10.1016/0304-3940(94)90331-X.CrossRefPubMed
44.
Hernanz A, Medina S, de Miguel E, Martin-Mola E: Effect of calcitonin gene-related peptide, neuropeptide Y, substance P, and vasoactive intestinal peptide on interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha production by peripheral whole blood cells from rheumatoid arthritis and osteoarthritis patients. Regul Pept. 2003, 115: 19-24. 10.1016/S0167-0115(03)00127-7.CrossRefPubMed
45.
Keeble JE, Brain SD: A role for substance P in arthritis?. Neurosci Lett. 2004, 361: 176-179. 10.1016/j.neulet.2003.12.020.CrossRefPubMed
46.
Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, et al: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 1998, 281: 1640-1645. 10.1126/science.281.5383.1640.CrossRefPubMed
47.
de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, Schmidt C, Evans JK, Horgan KJ: The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer. 2004, 40: 403-410. 10.1016/j.ejca.2003.08.028.CrossRefPubMed
48.
Kidd BL, Inglis JJ, Vetsika K, Hood VC, De Felipe C, Bester H, Hunt SP, Cruwys SC: Inhibition of inflammation and hyperalgesia in NK-1 receptor knock-out mice. Neuroreport. 2003, 14: 2189-2192. 10.1097/00001756-200312020-00011.CrossRefPubMed
49.
Stucchi AF, Shofer S, Leeman S, Materne O, Beer E, McClung J, Shebani K, Moore F, O'Brien M, Becker JM: NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats. Am J Physiol Gastrointest Liver Physiol. 2000, 279: G1298-1306.PubMed
50.
Foey AD, Field S, Ahmed S, Jain A, Feldmann M, Brennan FM, Williams R: Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis. Arthritis Res Ther. 2003, 5: R317-328. 10.1186/ar999.PubMedCentralCrossRefPubMed
51.
Juarranz MG, Santiago B, Torroba M, Gutierrez-Canas I, Palao G, Galindo M, Abad C, Martinez C, Leceta J, Pablos JL, et al: Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. Rheumatology (Oxford). 2004, 43: 416-422.CrossRef
52.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324.CrossRefPubMed
53.
Dixon A, Emery P: Local injection therapy in rheumatic disease. 1992, Basle: Eular Publishers, 4
54.
Hernanz A, Tato E, De la Fuente M, de Miguel E, Arnalich F: Differential effects of gastrin-releasing peptide, neuropeptide Y, somatostatin and vasoactive intestinal peptide on interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha production by whole blood cells from healthy young and old subjects. J Neuroimmunol. 1996, 71: 25-30. 10.1016/S0165-5728(96)00118-X.CrossRefPubMed
55.
Swaak AJ, van Rooyen A, Nieuwenhuis E, Aarden LA: Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases. Scand J Rheumatol. 1988, 17: 469-474.CrossRefPubMed
56.
Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T: Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004, 50: 1761-1769. 10.1002/art.20303.CrossRefPubMed
57.
Whiteside TL: Cytokine measurements and interpretation of cytokine assays in human disease. J Clin Immunol. 1994, 14: 327-339. 10.1007/BF01546317.CrossRefPubMed
58.
Lam FY, Ferrell WR: Mediators of substance P-induced inflammation in the rat knee joint. Agents Actions. 1990, 31: 298-307.CrossRefPubMed
59.
60.
Levine JD, Clark R, Devor M, Helms C, Moskowitz MA, Basbaum AI: Intraneuronal substance P contributes to the severity of experimental arthritis. Science. 1984, 226: 547-549.CrossRefPubMed
61.
Seegers HC, Avery PS, McWilliams DF, Haywood L, Walsh DA: Combined effect of bradykinin B2 and neurokinin-1 receptor activation on endothelial cell proliferation in acute synovitis. FASEB J. 2004, 18: 762-764.PubMed
62.
Iwasaki A, Inoue K, Hukuda S: Distribution of neuropeptide-containing nerve fibers in the synovium and adjacent bone of the rat knee joint. Clin Exp Rheumatol. 1995, 13: 173-178.PubMed
63.
Garrett NE, Kidd BL, Cruwys SC, Tomlinson DR: Changes in preprotachykinin mRNA expression and substance P levels in dorsal root ganglia of monoarthritic rats: comparison with changes in synovial substance P levels. Brain Res. 1995, 675: 203-207. 10.1016/0006-8993(95)00066-Y.CrossRefPubMed
64.
Konttinen YT, Hukkanen M, Segerberg M, Rees R, Kemppinen P, Sorsa T, Saari H, Polak JM, Santavirta S: Relationship between neuropeptide immunoreactive nerves and inflammatory cells in adjuvant arthritic rats. Scand J Rheumatol. 1992, 21: 55-59.CrossRefPubMed
65.
Watanabe T, Kubota Y, Muto T: Substance P containing nerve fibers in rectal mucosa of ulcerative colitis. Dis Colon Rectum. 1997, 40: 718-725.CrossRefPubMed
66.
Todorovic V, Janic B, Koko V, Micev M, Nikolic JA, Ratkovic M, Leposavic G, Jankovic T, Knezevic-Usaj S, Milicevic Z: Colonic vasoactive intestinal polypeptide (VIP) in ulcerative colitis – a radioimmunoassay and immunohistochemical study. Hepatogastroenterology. 1996, 43: 483-488.PubMed
67.
Gronblad M, Konttinen YT, Korkala O, Liesi P, Hukkanen M, Polak JM: Neuropeptides in synovium of patients with rheumatoid arthritis and osteoarthritis. J Rheumatol. 1988, 15: 1807-1810.PubMed
68.
Mapp PI, Kidd BL, Gibson SJ, Terry JM, Revell PA, Ibrahim NB, Blake DR, Polak JM: Substance P-, calcitonin gene-related peptide- and C-flanking peptide of neuropeptide Y-immunoreactive fibres are present in normal synovium but depleted in patients with rheumatoid arthritis. Neuroscience. 1990, 37: 143-153. 10.1016/0306-4522(90)90199-E.CrossRefPubMed
69.
Pereira da Silva JA, Carmo-Fonseca M: Peptide containing nerves in human synovium: immunohistochemical evidence for decreased innervation in rheumatoid arthritis. J Rheumatol. 1990, 17: 1592-1599.PubMed
70.
Matucci-Cerinic M, Lombardi A, Leoncini G, Pignone A, Sacerdoti L, Spillantini MG, Partsch G: Neutral endopeptidase (3.4.24.11) in plasma and synovial fluid of patients with rheumatoid arthritis. A marker of disease activity or a regulator of pain and inflammation?. Rheumatol Int. 1993, 13: 1-4. 10.1007/BF00290326.CrossRefPubMed
71.
Matucci-Cerinic M, Partsch G, Marabini S, Cagnoni M: High levels of substance P in rheumatoid arthritis synovial fluid. Lack of substance P production by synoviocytes in vitro. Clin Exp Rheumatol. 1991, 9: 440-441.PubMed
72.
Marshall KW, Chiu B, Inman RD: Substance P and arthritis: analysis of plasma and synovial fluid levels. Arthritis Rheum. 1990, 33: 87-90.CrossRefPubMed
73.
Iannone F, Lapadula G: Neuropeptides and human osteoarthritis. J Rheumatol. 1998, 25: 386-388.PubMed
74.
Carney DN, Cuttitta F, Moody TW, Minna JD: Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide. Cancer Res. 1987, 47: 821-825.PubMed
75.
Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, Minna JD: Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature. 1985, 316: 823-826. 10.1038/316823a0.CrossRefPubMed
76.
Saurin JC, Nemoz-Gaillard E, Sordat B, Cuber JC, Coy DH, Abello J, Chayvialle JA: Bombesin stimulates adhesion, spreading, lamellipodia formation, and proliferation in the human colon carcinoma Isreco1 cell line. Cancer Res. 1999, 59: 962-967.PubMed
77.
Aalto Y, Kjorell U, Henriksson R, Franzen L, Forsgren S: Bombesin-like peptide is present in duct cells in salivary glands: studies on normal and irradiated animals. Neuropeptides. 1997, 31: 167-173. 10.1016/S0143-4179(97)90086-X.CrossRefPubMed
78.
Hill DJ, McDonald TJ: Mitogenic action of gastrin-releasing polypeptide on isolated epiphyseal growth plate chondrocytes from the ovine fetus. Endocrinology. 1992, 130: 2811-2819. 10.1210/en.130.5.2811.PubMed
79.
Matkowskyj KA, Keller K, Glover S, Kornberg L, Tran-Son-Tay R, Benya RV: Expression of GRP and its receptor in well-differentiated colon cancer cells correlates with the presence of focal adhesion kinase phosphorylated at tyrosines 397 and 407. J Histochem Cytochem. 2003, 51: 1041-1048.CrossRefPubMed
80.
Westermark T, Isaksson T, Holmberg P, Kjorell U, Rantapaa-Dahlqvist S, Forsgren S: Dexamethasone treatment after adrenalectomy increases bombesin content in the rat spinal cord [abstract]. Acta Physiol Scand. 1999, 167: A8-10.1046/j.1365-201x.1999.0600h.x.CrossRefPubMed
81.
Alican I, Unluer EE, Yegen C, Yegen BC: Bombesin improves burn-induced intestinal injury in the rat. Peptides. 2000, 21: 1265-1269. 10.1016/S0196-9781(00)00268-0.CrossRefPubMed
82.
Lemaire I, Jones S, Khan MF: Bombesin-like peptides in alveolar macrophage: increased release in pulmonary inflammation and fibrosis. Neuropeptides. 1991, 20: 63-72. 10.1016/0143-4179(91)90041-G.CrossRefPubMed
83.
Gulluoglu BM, Kurtel H, Gulluoglu MG, Aktan AO, Yegen BC, Dizdaroglu F, Yalin R: Bombesin ameliorates colonic damage in experimental colitis. Dig Dis Sci. 1999, 44: 1531-1538. 10.1023/A:1026646523284.CrossRefPubMed
84.
Yegen BC: Bombesin-like peptides: candidates as diagnostic and therapeutic tools. Curr Pharm Des. 2003, 9: 1013-1022. 10.2174/1381612033455134.CrossRefPubMed
85.
Yamaguchi Y, Hosokawa K, Nakatani Y, Sano S, Yoshikawa K, Itami S: Gastrin-releasing peptide, a bombesin-like neuropeptide, promotes cutaneous wound healing. Dermatol Surg. 2002, 28: 314-319. 10.1046/j.1524-4725.2002.99279.x.PubMed
86.
Williams RO: Therapeutic effect of vasoactive intestinal peptide in collagen-induced arthritis. Arthritis Rheum. 2002, 46: 271-273. 10.1002/1529-0131(200201)46:1<271::AID-ART10039>3.0.CO;2-C.CrossRefPubMed
87.
Palmblad K: Cytokines and cytokine-directed intervention in experimental arthritis. PhD thesis. 2001, Karolinska Institute, Department of Woman and Child Health
88.
Özenci V: Immune regulation in multiple sclerosis: Cytokines and metalloproteinases. PhD thesis. 2000, Karolinska Institute, Division of Neurology
89.
Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, Bekker P: Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 2004, 50: 1412-1419. 10.1002/art.20221.CrossRefPubMed
90.
Zhou J, Chen J, Mokotoff M, Zhong R, Shultz LD, Ball ED: Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer. Clin Cancer Res. 2003, 9: 4953-4960.PubMed
91.
Sakai K, Matsuno H, Tsuji H, Tohyama M: Substance P receptor (NK1) gene expression in synovial tissue in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol. 1998, 27: 135-141. 10.1080/030097498441010.CrossRefPubMed
Metadata
Title
Levels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis
Authors
Ola Grimsholm
Solbritt Rantapää-Dahlqvist
Sture Forsgren
Publication date
01-03-2005
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 3/2005
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1503

Other articles of this Issue 3/2005

Arthritis Research & Therapy 3/2005 Go to the issue

Research article

Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey

Research article

Signalling pathway involved in nitric oxide synthase type II activation in chondrocytes: synergistic effect of leptin with interleukin-1

Research article

Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]

Research article

Quantitative ultrasound can assess the regeneration process of tissue-engineered cartilage using a complex between adherent bone marrow cells and a three-dimensional scaffold

Research article

Peripheral blood but not synovial fluid natural killer T cells are biased towards a Th1-like phenotype in rheumatoid arthritis

Research article

Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits